Pharmicell Co Ltd (XKRX:005690) Share Price

Company Profile

Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KOR
T: +82 234960114
http://www.pharmicell.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
146

Recommended

Going back to my original thesis to evaluate a position.

Mark LaMonica, CFA | 08 August 2025

This company dominates its industry and could be flirting with regulatory intervention.

Roy Van Keulen | 07 August 2025

Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.

Mark Giarelli | 07 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,076.60	25.40	-0.28%
CAC 40	7,743.00	33.68	0.44%
DAX 40	24,162.86	29.64	-0.12%
Dow JONES (US)	44,175.61	206.97	0.47%
FTSE 100	9,095.73	5.04	-0.06%
HKSE	24,858.82	222.81	-0.89%
NASDAQ	21,450.02	207.32	0.98%
Nikkei 225	41,820.48	761.33	1.85%
NZX 50 Index	12,844.63	42.47	-0.33%
S&P 500	6,389.45	49.45	0.78%
S&P/ASX 200	8,807.10	24.30	-0.28%
SSE Composite Index	3,635.13	4.54	-0.12%